Regulations are stifling development of new drugs

BMJ 2004; 328 doi: (Published 11 March 2004) Cite this as: BMJ 2004;328:600
  1. Zosia Kmietowicz
  1. London

    The volumes of regulations that surround scientific research are stifling the development of new drugs and need to be rationalised if innovative discoveries in biology are to be matched with new medicines and demand by patients for better treatments, said experts this week.

    It costs an estimated $800m (£433m; €645m) to get a new drug to the market, and pharmaceutical companies have to hit …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription